首页> 外文期刊>BMC Biotechnology >Experimental design approach in recombinant protein expression: determining medium composition and induction conditions for expression of pneumolysin from Streptococcus pneumoniae in Escherichia coli and preliminary purification process
【24h】

Experimental design approach in recombinant protein expression: determining medium composition and induction conditions for expression of pneumolysin from Streptococcus pneumoniae in Escherichia coli and preliminary purification process

机译:重组蛋白表达的实验设计方法:确定肺炎链球菌肺炎球菌溶血素在大肠杆菌中表达的培养基组成和诱导条件及初步纯化工艺

获取原文
           

摘要

Background Streptococcus pneumoniae (S. pneumoniae) causes several serious diseases including pneumonia, septicemia and meningitis. The World Health Organization estimates that streptococcal pneumonia is the cause of approximately 1.9 million deaths of children under five years of age each year. The large number of serotypes underlying the disease spectrum, which would be reflected in the high production cost of a commercial vaccine effective to protect against all of them and the higher level of amino acid sequence conservation as compared to polysaccharide structure, has prompted us to attempt to use conserved proteins for the development of a simpler vaccine. One of the most prominent proteins is pneumolysin (Ply), present in almost all the serotypes known at the moment, which shows an effective protection against S. pneumoniae infections. Results We have cloned the pneumolysin gene from S. pneumoniae serotype 14 and studied the effects of eight variables related to medium composition and induction conditions on the soluble expression of rPly in Escherichia coli ( E. coli) and a 28-4 factorial design was applied. Statistical analysis was carried out to compare the conditions used to evaluate the expression of soluble pneumolysin; rPly activity was evaluated by hemolytic activity assay and served as the main response to evaluate the proper protein expression and folding. The optimized conditions, validated by the use of triplicates, include growth until an absorbance of 0.8 (measured at 600?nm) with 0.1?mM IPTG during 4?h at 25°C in a 5?g/L yeast extract, 5?g/L tryptone, 10?g/L NaCl, 1?g/L glucose medium, with addition of 30?μg/mL kanamycin. Conclusions This experimental design methodology allowed the development of an adequate process condition to attain high levels (250?mg/L) of soluble expression of functional rPly in E. coli , which should contribute to reduce operational costs. It was possible to recover the protein in its active form with 75% homogeneity.
机译:背景肺炎链球菌(S. pneumoniae)引起几种严重的疾病,包括肺炎,败血病和脑膜炎。世界卫生组织估计,链球菌性肺炎是每年导致190万五岁以下儿童死亡的原因。疾病谱中存在大量血清型,这反映在可有效预防所有血清型的商业疫苗的高生产成本以及与多糖结构相比更高水平的氨基酸序列保守性上,促使我们尝试使用保守的蛋白质来开发更简单的疫苗。最突出的蛋白质之一是肺炎球菌溶血素(Ply),目前存在于几乎所有血清型中,显示出对肺炎链球菌感染的有效保护。结果我们已经从肺炎链球菌血清型14克隆了肺炎球菌溶血素基因,研究了与培养基组成和诱导条件有关的八个变量对rPly在大肠杆菌(E. coli)中的可溶性表达和2 ^ 8-4的影响。 采用了析因设计。进行统计分析以比较用于评估可溶性肺炎球菌溶血素表达的条件; rPly活性通过溶血活性测定进行评估,并用作评估正确蛋白质表达和折叠的主要反应。通过一式三份验证了优化的条件,包括在25℃,5?g / L的酵母提取物中,在25°C下4?h内生长直至0.1?mM IPTG吸收到0.8(在600?nm处测量)。 g / L胰蛋白,、 10?g / L NaCl,1?g / L葡萄糖培养基,以及30?μg/ mL卡那霉素。结论该实验设计方法允许开发适当的工艺条件以在大肠杆菌中达到高水平(250?mg / L)的功能性rPly可溶性表达,这应有助于降低运营成本。有可能以75%的同质性回收其活性形式的蛋白质。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号